Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial (2022) Eichinger A, Poetschger U, Glogova E, Bader P, Basu O, Beier R, Burkhardt B, et al. Journal article Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial (2022) Zimmermann H, Koenecke C, Dreyling MH, Pott C, Duehrsen U, Hahn D, Meidenbauer N, et al. Journal article ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia (2022) Schoenfeld L, Rinke J, Hinze A, Nagel SN, Schaefer V, Schenk T, Fabisch C, et al. Journal article Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia (2022) Roehnert MA, Kramer M, Schadt J, Ensel P, Thiede C, Krause S, Buecklein V, et al. Journal article Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9) (2022) Cesaro S, Ljungman P, Mikulska M, Hirsch HH, Von Lilienfeld-Toal M, Cordonnier C, Meylan S, et al. Journal article, Review article Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial (2022) Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, Falautano M, et al. Journal article LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma (2022) Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, Cavo M, et al. Journal article Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression (2022) Dahlhoff J, Manz H, Steinfatt T, Delgado-Tascon J, Seebacher E, Schneider T, Wilnit A, et al. Journal article JunB is a key regulator of multiple myeloma bone marrow angiogenesis (2021) Fan F, Malvestiti S, Vallet S, Lind J, Garcia-Manteiga JM, Morelli E, Jiang Q, et al. Journal article Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab (2021) Garcia-Guerrero E, Goetz R, Doose S, Sauer M, Rodriguez-Gil A, Nerreter T, Kortuem KM, et al. Journal article